Physician profile
Jeffrey Daniel Smith
NPI 1376103630
$575.71
in general payments reported to CMS, 2019-2025
9 companies · $331 in 2025
The $331 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $45.72 · 2024: $199 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $529.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $179.96 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Inari Medical, INC. | $147.43 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $61.30 | 2020-2025 | Breztri, Airsupra |
| Insmed, INC. | $55.72 | 2025 | Brinsupri, Arikayce |
| Genzyme Corporation | $40.47 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.06 | 2024-2025 | Aralast |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.32 | 2025 | |
| Azurity Pharmaceuticals, INC. | $18.48 | 2025 | Alvesco |
| Sanofi-Aventis U.S. LLC | $14.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.